Utilico Insights - Jacqueline Broers assesses why Vietnam could be the darling of Asia for investors. Watch the full video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksC4x Discry Hdgs Regulatory News (C4XD)

Share Price Information for C4x Discry Hdgs (C4XD)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 9.64
Bid: 9.30
Ask: 9.98
Change: 0.00 (0.00%)
Spread: 0.68 (7.312%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 9.64
C4XD Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Result of AGM

31 Jan 2017 13:06

RNS Number : 6203V
C4X Discovery Holdings PLC
31 January 2017
 

 

 

C4X Discovery Holdings plc

("C4XD" or the "Company")

 

Result of AGM

 

31 January, 2017 - C4X Discovery Holdings plc (AIM: C4XD), a pioneering drug discovery company, announces that at its Annual General Meeting held today at 12:00 noon at The Podium, Euston, 1 Eversholt Street, London NW1 1AD, all resolutions were duly passed.

 

 

--ENDS-

For further information, please contact:

C4X Discovery Holdings plc

Clive Dix, Chief Executive Officer 07801 865 803

 

Zeus Capital Limited

Dan Bate 0161 831 1512

Dominic Wilson/Phil Walker 0203 829 5000

 

Consilium Strategic Communications

Mary-Jane Elliott, Matthew Neal, Melissa Gardiner 0203 709 5700 

 

About C4X Discovery

 

C4X Discovery aims to become the world's most productive drug discovery engine by exploiting cutting edge technologies to design and create best-in-class small-molecule candidates targeting a range of high value therapeutic areas. The company's goal is to drive returns through early-stage revenue-generating deals with the pharmaceutical industry.

 

C4X Discovery has a state-of-the-art suite of proprietary technologies across the drug discovery process. The company's innovative DNA-based target identification platform (Taxonomy3®) utilises human genetic datasets to identify novel patient-specific targets leading to greater discovery productivity and increased probability of clinical success. This is complemented by C4X's novel drug design platform which comprises two innovative chemistry technologies, Conformetrix and Molplex that combine 4D molecular shape analyses (based on experimental data) with best-in-class computational chemistry. This provides new and unprecedented insight into the behaviour of drug molecules, enabling the production of potent selective compounds faster and more cost effectively than the industry standard.

 

C4X Discovery is advancing its in-house pipeline in addiction, diabetes and inflammation with a number of new drug candidates identified and further progress made towards the clinic. In selecting new targets C4X Discovery will focus on the high-value disease areas of inflammation and neurodegeneration, and will continue to maximise value from opportunistic areas, for example, immuno-oncology.

 

The Company was founded as a spin-out from the University of Manchester. It has a highly experienced management team and Board who have delivered significant value creation within the healthcare sector historically and have enabled C4X to reach multiple value inflexion points since IPO. For additional information please go to: www.c4xdiscovery.com

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RAGBXGDBUGXBGRB
Date   Source Headline
27th Mar 20247:00 amRNSProposed Voluntary Delisting
27th Mar 20247:00 amRNSInterim results
23rd Jan 20241:57 pmRNSResult of AGM
18th Jan 20247:00 amRNSBoard Update
4th Jan 20242:45 pmRNSHolding(s) in Company
3rd Jan 20247:00 amRNSAstraZeneca $11m milestone payment to C4XD
18th Dec 20233:31 pmRNSPosting of 2023 Annual Report and Notice of AGM
14th Dec 20237:00 amRNSFull Year Results
7th Dec 20237:00 amRNSNotice of Results
5th Oct 20232:35 pmRNSHolding(s) in Company
2nd Oct 202312:36 pmRNSBlock listing Interim Review
29th Sep 202311:14 amRNSGrant of Options and Directors Dealing
28th Sep 20233:52 pmRNSHolding(s) in Company
1st Sep 20237:00 amRNSTotal Voting Rights
18th Aug 202312:45 pmRNSExercise of Options, Issue of Equity and TVR
1st Aug 20237:00 amRNSDivestment of Orexin-1 to Indivior for £15.95m
20th Jun 20237:00 amRNSC4X Discovery Holdings plc: Board Change
1st Jun 20237:00 amRNSMALT-1 Inhibitor Programme Update
26th Apr 20237:00 amRNSHalf Year Results
19th Apr 20237:00 amRNSNotice of Results
8th Mar 20232:49 pmRNSBlock Listing Interim Review
22nd Feb 20237:00 amRNSC4XD and Garvan Institute collaboration
24th Jan 202311:47 amRNSResult of AGM
19th Jan 20237:00 amRNSMALT-1 Inhibitor Programme Update
10th Jan 20237:00 amRNSNick Ray Appointed as Chief Scientific Officer
19th Dec 20224:52 pmRNSPosting of 2022 Annual Report and Notice of AGM
15th Dec 20227:00 amRNSFull Year Results
28th Nov 20222:31 pmEQSC4X Discovery signs potential $402mln deal
28th Nov 20229:00 amRNSNotice of Final Results
28th Nov 20227:00 amRNSC4XD Agreement with AstraZeneca
1st Nov 20222:03 pmRNSExercise of Options, Issue of Equity and TVR
20th Oct 20227:00 amRNSC4XD and HitGen to collaborate in inflammation
4th Oct 20222:56 pmRNSHolding(s) in Company
22nd Sep 20224:40 pmRNSSecond Price Monitoring Extn
22nd Sep 20224:35 pmRNSPrice Monitoring Extension
31st Aug 202211:10 amRNSHolding(s) in Company
17th Aug 20224:06 pmRNSHolding(s) in Company
17th Aug 20223:43 pmRNSHolding(s) in Company
16th Aug 20222:17 pmRNSHolding(s) in Company
11th Aug 202212:43 pmRNSResult of Placing to Raise £5.7 million
11th Aug 20227:00 amRNSProposed Placing to Raise Up To £5.7 million
2nd Aug 20227:00 amRNSBusiness Update
1st Aug 20223:09 pmRNSBlock Listing Interim Review
6th Jul 20227:00 amRNSC4X Discovery receives Sanofi milestone payment
28th Jun 20225:46 pmRNSAIM Rule 17 Schedule 2(g) Update
28th Apr 20227:00 amRNSHalf Year Results
19th Apr 20227:00 amRNSNotice of Results
28th Feb 20225:30 pmRNSExercise of Options, Issue of Equity and TVR
3rd Feb 20227:00 amRNSGrant of Options and Directors Dealing
1st Feb 20227:00 amRNSBlock listing Return

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.